Table 1.
Hemodynamic, ventriculographic, echocardiographic-Doppler and electrolyte measurements obtained at pre-treatment and at 1 week and 12 weeks after initiating follow-up in control group and Capadenoson (CAP)-treated group.
| Pretreatment | 1 weeks | 12 weeks | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Control | CAP | P- value | Control | CAP | P- value | Control | CAP | P value - | |
| HR (beats/min) | 87±2.9 | 89±4.4 | 0.71 | 88±2.7 | 80±2.4 | 0.05 | 85±3.9 | 84±2.9 | 0.84 |
| mAoP (mmHg) | 72±2.0 | 78±2.0 | 0.06 | 81±3.9 | 84±6.5 | 0.70 | 78±1.9 | 77±5.0 | 0.86 |
| LVEDP (mmHg) | 17±1.2 | 17±1.5 | 1.0 | 19±1.6 | 15±0.9 | 0.05 | 17±1.3 | 14±1.4 | 0.15 |
| LVEDV (ml) | 73±4 | 70±4.2 | 0.62 | 74±3.8 | 70±4.4 | 0.51 | 83±3.1† | 72±6.6 | 0.16 |
| LVESV (ml) | 51±3.5 | 51±3.9 | 1.0 | 52±3.4 | 45±4.1 | 0.22 | 60±2.9† | 44±6.2 | 0.04 |
| LVEF (%) | 30±1.9 | 27±1.8 | 0.28 | 30±2.0 | 36±2.1* | 0.06 | 27±1.4† | 39±2.4* | 0.002 |
| LVESP (mm Hg) | 74±2.1 | 78±2.8 | 0.28 | 77±2.6 | 86±7.7 | 0.29 | 78±3.5 | 79±5.6 | 0.88 |
| LV+dP/dt (mmHg/sec) | 1352±126 | 1589±185 | 0.32 | 1307±37 | 1812±180 | 0.02 | 1357±73 | 1752±281 | 0.20 |
| Tau (msec) | 59±6 | 60±10 | 0.93 | 73±10 | 51±4 | 0.07 | 67±13 | 48±5 | 0.21 |
| SV (ml) | 21±2 | 19±1 | 0.29 | 22±2 | 25±1* | 0.16 | 23±1 | 28±1* | 0.008 |
| CO (L/min) | 1.83±0.11 | 1.69±0.12 | 0.41 | 1.91±0.14 | 1.99±0.10* | 0.65 | 1.93±0.11 | 2.30±0.10* | 0.03 |
| SVR (dynes/sec/cm−5) | 3292±281 | 3776±323 | 0.28 | 3395±145 | 3422±319 | 0.94 | 3486±279 | 2661±114* | 0.02 |
| Ei/Ai | 3.37±0.41 | 3.82±0.49 | 0.50 | 3.66±0.49 | 4.23±0.45 | 0.41 | 3.82±0.3 | 4.55±0.56 | 0.28 |
| DT (msec) | 92±6 | 103±9 | 0.33 | 84±5 | 108±8 | 0.03 | 88±5 | 107±9 | 0.09 |
| LV EDWS (gm/cm2) | 86±15 | 73±9 | 0.47 | 87±11 | 63±7 | 0.09 | 99±18 | 64±14 | 0.16 |
| Slope-ESPVR (mmHg/ml) (n=3 per group) | 2.72 ± 0.62 | 1.54 ± 0.20 | 0.1 | --- | --- | --- | 1.51 ± 0.29 | 1.31 ± 0.18 | 0.57 |
| Creatinine (mg/dL) | 0.92±0.04 | 0.93±0.05 | 0.88 | 0.93±0.03 | 0.92±0.05 | 0.87 | 0.90±0.06 | 1.00±0.07 | 0.30 |
| BUN (mg/dL) | 13±1 | 13±1 | 1.0 | 15±2 | 14±1 | 0.66 | 15±1 | 14±2 | 0.66 |
| Plasma NE (pg/ml) | --- | 908±127 | --- | --- | 520±35* | --- | --- | 210±21* | --- |
Data are shown as Mean ± SEM. HR = heart rate; mAoP = mean aortic pressure; LV = left ventricular; EDP = end-diastolic pressure; EDV = end-diastolic volume; ESV = end-systolic volume; EF = ejection fraction; ESP=end-systolic pressure; +dP/dt=peak rate of change of pressure during isovolumic period; Tau=time constant of isovolumic relaxation; SV = stroke volume; CO = cardiac output; SVR = systemic vascular resistance; Ei = time-velocity integral of the mitral inflow velocity waveform representing early filling; Ai = time-velocity integral representing LA contraction; Ei/Ai = ratio of Ei to Ai; DT = deceleration time of early mitral inflow velocity; EDWS = LV end-diastolic circumferential wall stress; ESPVR=end-systolic pressure-volume relationship; BUN=blood urea nitrogen; NE=norepinephrine. P-value=probability value of control vs. Capadenoson (CAP) at pre-treatment, 1 week and 12 weeks.
p<0.05 vs. pre-treatment in Capadenoson group;
p<0.05 vs. pre-treatment in control group.